Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical Gel

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Actinic Keratosis

Conditions

Actinic Keratosis

Trial Timeline

Oct 1, 2012 → Oct 1, 2013

NCT ID

NCT01742663

About Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical Gel

Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical Gel is a phase 1 stage product being developed by Sun Pharmaceutical for Actinic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01742663. Target conditions include Actinic Keratosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01742663	Phase 1	Completed	Oct 1, 2012	Oct 1, 2013	Actinic Keratosis

Competing Products

20 competing products in Actinic Keratosis

See all competitors

Product	Company	Stage	Hype Score
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%	Sun Pharmaceutical	Phase 3	77
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%	Sun Pharmaceutical	Phase 3	77
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical Cream	Sun Pharmaceutical	Phase 1	33
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by Taro	Sun Pharmaceutical	Phase 1	33
Investigational Treatment + Active comparator	Novartis	Phase 2	52
KX01 ointment 1% + Placebo	PharmaEssentia	Phase 3	76
Fluorouracil	Sanofi	Phase 1/2	40
fluorouracil cream 0.5%	Sanofi	Approved	84
Imiquimod + Diclofenac	Viatris	Approved	82
Imiquimod 5 % Cream	Viatris	Phase 2	49
Imiquimod	Viatris	Pre-clinical	20
Aldara (Imiquimod)	Viatris	Phase 3	74
Imiquimod + Diclofenac	Viatris	Approved	82
Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice daily	Dr. Reddy's Laboratories	Phase 2/3	62
Placebo Gel + LAS41005 + LAS106521	Almirall	Phase 3	72
5-fluorouracil/salicylic acid + Vehicle	Almirall	Phase 3	72
50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%	Almirall	Phase 2	47
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% Gel	Almirall	Approved	80
KX2-391 Ointment 1% + Placebo	Almirall	Phase 3	72
Tirbanibulin 2.5 mg ointment	Almirall	Approved	80

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved

CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved

Cyclosporine + Artificial tearApproved

AmifostineApproved

Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved